Cargando…

Effects of exenatide on cardiac function, perfusion, and energetics in type 2 diabetic patients with cardiomyopathy: a randomized controlled trial against insulin glargine

BACKGROUND: Multiple bloodglucose-lowering agents have been linked to cardiovascular events. Preliminary studies showed improvement in left ventricular (LV) function during glucagon-like peptide-1 receptor agonist administration. Underlying mechanisms, however, are unclear. The purpose of this study...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Weena J. Y., Diamant, Michaela, de Boer, Karin, Harms, Hendrik J., Robbers, Lourens F. H. J., van Rossum, Albert C., Kramer, Mark H. H., Lammertsma, Adriaan A., Knaapen, Paul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5438489/ https://www.ncbi.nlm.nih.gov/pubmed/28526033 http://dx.doi.org/10.1186/s12933-017-0549-z

Ejemplares similares

Parametric imaging of myocardial viability using (15)O-labelled water and PET/CT: comparison with late gadolinium-enhanced CMR
por: de Haan, Stefan, et al.
Publicado: (2012)

In vivo assessment of myocardial viability after acute myocardial infarction: A head-to-head comparison of the perfusable tissue index by PET and delayed contrast-enhanced CMR
por: Timmer, Stefan A. J., et al.
Publicado: (2016)

Safety and Efficacy of Once-Weekly Exenatide Compared With Insulin Glargine Titrated to Target in Patients With Type 2 Diabetes Over 84 Weeks
por: Diamant, Michaela, et al.
Publicado: (2012)

ENerGetIcs in hypertrophic cardiomyopathy: traNslation between MRI, PET and cardiac myofilament function (ENGINE study)
por: Güçlü, A., et al.
Publicado: (2013)

Feasibility of subendocardial and subepicardial myocardial perfusion measurements in healthy normals with (15)O-labeled water and positron emission tomography
por: Vermeltfoort, Ilse A., et al.
Publicado: (2011)

Automatic generation of absolute myocardial blood flow images using [(15)O]H(2)O and a clinical PET/CT scanner
por: Harms, Hendrik J., et al.
Publicado: (2011)

One-Year Treatment With Exenatide Improves β-Cell Function, Compared With Insulin Glargine, in Metformin-Treated Type 2 Diabetic Patients: A randomized, controlled trial
por: Bunck, Mathijs C., et al.
Publicado: (2009)

Relationship of body mass index with efficacy of exenatide twice daily added to insulin glargine in patients with type 2 diabetes
por: Wolffenbuttel, B. H. R., et al.
Publicado: (2016)

Effect of additional treatment with EXenatide in patients with an Acute Myocardial Infarction (EXAMI): study protocol for a randomized controlled trial
por: Scholte, Martijn, et al.
Publicado: (2011)

Patient-reported outcomes in a trial of exenatide and insulin glargine for the treatment of type 2 diabetes
por: Secnik Boye, Kristina, et al.
Publicado: (2006)

Diabetic cardiomyopathy in Zucker diabetic fatty rats: the forgotten right ventricle
por: van den Brom, Charissa E, et al.
Publicado: (2010)

Exenatide Affects Circulating Cardiovascular Risk Biomarkers Independently of Changes in Body Composition
por: Bunck, Mathijs C., et al.
Publicado: (2010)

Comparison of Glycemic Variability in Chinese T2DM Patients Treated with Exenatide or Insulin Glargine: A Randomized Controlled Trial
por: Yin, Ting-Ting, et al.
Publicado: (2018)

Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial
por: Tonneijck, Lennart, et al.
Publicado: (2016)

Acute plasma amylase increase after glucagon‐like peptide ‐1 receptor agonist exenatide administration in Type 2 diabetes
por: Smits, M. M., et al.
Publicado: (2017)

Treatment of patients with type 2 diabetes with exenatide once weekly versus oral glucose-lowering medications or insulin glargine: achievement of glycemic and cardiovascular goals
por: Meloni, Alison R, et al.
Publicado: (2013)

Liver Fat Content in Type 2 Diabetes: Relationship With Hepatic Perfusion and Substrate Metabolism
por: Rijzewijk, Luuk J., et al.
Publicado: (2010)

Evaluation of the cost effectiveness of exenatide versus insulin glargine in patients with sub-optimally controlled Type 2 diabetes in the United Kingdom
por: Woehl, Anette, et al.
Publicado: (2008)

Effects of exenatide versus insulin glargine on body composition in overweight and obese T2DM patients: a randomized controlled trial
por: Yin, Ting-Ting, et al.
Publicado: (2018)

Insulin Glargine is More Suitable Than Exenatide in Preventing Muscle Loss in Non-Obese Type 2 Diabetic Patients with NAFLD
por: Liu, Lin, et al.
Publicado: (2023)

Comparison of insulin lispro protamine suspension versus insulin glargine once daily added to oral antihyperglycaemic medications and exenatide in type 2 diabetes: a prospective randomized open-label trial
por: Arakaki, R F, et al.
Publicado: (2014)

Quantitative relationship between coronary artery calcium score and hyperemic myocardial blood flow as assessed by hybrid (15)O-water PET/CT imaging in patients evaluated for coronary artery disease
por: Danad, Ibrahim, et al.
Publicado: (2011)

Further Improvement in Postprandial Glucose Control With Addition of Exenatide or Sitagliptin to Combination Therapy With Insulin Glargine and Metformin: A proof-of-concept study
por: Arnolds, Sabine, et al.
Publicado: (2010)

Medication utilization patterns among type 2 diabetes patients initiating Exenatide BID or insulin glargine: a retrospective database study
por: Pawaskar, Manjiri, et al.
Publicado: (2013)

Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: The DURATION‐7 randomized study
por: Guja, Cristian, et al.
Publicado: (2018)

The effects of exenatide and insulin glargine treatments on bone turnover markers and bone mineral density in postmenopausal patients with type 2 diabetes mellitus
por: Akyay, Ozlem Zeynep, et al.
Publicado: (2023)

Glucagon and exenatide improve contractile recovery following ischaemia/reperfusion in the isolated perfused rat heart
por: Lindsay, Ross T., et al.
Publicado: (2023)

Obesity modifies the energetic phenotype of dilated cardiomyopathy
por: Rayner, Jennifer J, et al.
Publicado: (2021)

Altered myocardial substrate metabolism is associated with myocardial dysfunction in early diabetic cardiomyopathy in rats: studies using positron emission tomography
por: van den Brom, Charissa E, et al.
Publicado: (2009)

Impaired myocardial perfusion on CMR is associated with increased numbers of classical monocytes in STEMI patients treated by primary PCI
por: Robbers, Lourens FHJ, et al.
Publicado: (2011)

Quantification of [(11)C]-meta-hydroxyephedrine uptake in human myocardium
por: Harms, Hendrik J, et al.
Publicado: (2014)

Effects of Exenatide on Measures of β-Cell Function After 3 Years in Metformin-Treated Patients With Type 2 Diabetes
por: Bunck, Mathijs C., et al.
Publicado: (2011)

Coronary risk factors and myocardial blood flow in patients evaluated for coronary artery disease: a quantitative [(15)O]H(2)O PET/CT study
por: Danad, Ibrahim, et al.
Publicado: (2011)

Baseline Factors Associated With Glycemic Control and Weight Loss When Exenatide Twice Daily Is Added to Optimized Insulin Glargine in Patients With Type 2 Diabetes
por: Rosenstock, Julio, et al.
Publicado: (2012)

Evaluation of extracorporeal shock wave therapy for refractory angina pectoris with quantitative analysis using cardiac magnetic resonance imaging: a short communication
por: Slikkerveer, J., et al.
Publicado: (2016)

Exenatide Improves Glucose Homeostasis and Prolongs Survival in a Murine Model of Dilated Cardiomyopathy
por: Vyas, Arpita Kalla, et al.
Publicado: (2011)

Comparison between quantitative cardiac magnetic resonance perfusion imaging and [(15)O]H(2)O positron emission tomography
por: Everaars, Henk, et al.
Publicado: (2019)

Pancreatitis Incidence in the Exenatide BID, Exenatide QW, and Exenatide QW Suspension Development Programs: Pooled Analysis of 35 Clinical Trials
por: Vetter, Marion L., et al.
Publicado: (2019)

Myocardial perfusion imaging with PET
por: Driessen, Roel S., et al.
Publicado: (2017)

Activin a is associated with impaired myocardial glucose metabolism and left ventricular remodeling in patients with uncomplicated type 2 diabetes
por: Chen, Weena JY, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_0mo56187vdp5t4nsqlq0qd7mv4